DVAX Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 9.79% compared to Dynavax Technologies's net margin of 19.72%. Dynavax Technologies's return on equity of 4.32% beat Gilead Sciences's return on equity of 32.29%.

Dynavax Technologies has a consensus price target of $24.25, signalling upside risk potential of 124.12%. On the other hand Gilead Sciences has an analysts' consensus of $113.75 which suggests that it could grow by 10.26%. Given that Dynavax Technologies has higher upside potential than Gilead Sciences, analysts believe Dynavax Technologies is more attractive than Gilead Sciences.

Dynavax Technologies has a beta of 1.265, which suggesting that the stock is 26.451% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.01% to investors and pays a quarterly dividend of $0.79 per share. Dynavax Technologies pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Dynavax Technologies quarterly revenues are $72M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Dynavax Technologies's net income of $7.1M is lower than Gilead Sciences's net income of $1.3B. Notably, Dynavax Technologies's price-to-earnings ratio is 60.11x while Gilead Sciences's PE ratio is 21.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 5.58x versus 4.53x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of 9.79% compared to Dynavax Technologies's net margin of -46.06%. Dynavax Technologies's return on equity of 4.32% beat Ionis Pharmaceuticals's return on equity of -103.27%.

Dynavax Technologies has a consensus price target of $24.25, signalling upside risk potential of 124.12%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $57.31 which suggests that it could grow by 92.96%. Given that Dynavax Technologies has higher upside potential than Ionis Pharmaceuticals, analysts believe Dynavax Technologies is more attractive than Ionis Pharmaceuticals.

Dynavax Technologies has a beta of 1.265, which suggesting that the stock is 26.451% more volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.35%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Dynavax Technologies quarterly revenues are $72M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $226.6M. Dynavax Technologies's net income of $7.1M is higher than Ionis Pharmaceuticals's net income of -$104.3M. Notably, Dynavax Technologies's price-to-earnings ratio is 60.11x while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 5.58x versus 6.30x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 9.79% compared to Dynavax Technologies's net margin of 32.59%. Dynavax Technologies's return on equity of 4.32% beat Eli Lilly and's return on equity of 80.24%.

Dynavax Technologies has a consensus price target of $24.25, signalling upside risk potential of 124.12%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 14.03%. Given that Dynavax Technologies has higher upside potential than Eli Lilly and, analysts believe Dynavax Technologies is more attractive than Eli Lilly and.

Dynavax Technologies has a beta of 1.265, which suggesting that the stock is 26.451% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.61% to investors and pays a quarterly dividend of $1.50 per share. Dynavax Technologies pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dynavax Technologies quarterly revenues are $72M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Dynavax Technologies's net income of $7.1M is lower than Eli Lilly and's net income of $4.4B. Notably, Dynavax Technologies's price-to-earnings ratio is 60.11x while Eli Lilly and's PE ratio is 75.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 5.58x versus 17.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 9.79% compared to Dynavax Technologies's net margin of -117.16%. Dynavax Technologies's return on equity of 4.32% beat Moderna's return on equity of -29.09%.

Dynavax Technologies has a consensus price target of $24.25, signalling upside risk potential of 124.12%. On the other hand Moderna has an analysts' consensus of $49.96 which suggests that it could grow by 83.55%. Given that Dynavax Technologies has higher upside potential than Moderna, analysts believe Dynavax Technologies is more attractive than Moderna.

Dynavax Technologies has a beta of 1.265, which suggesting that the stock is 26.451% more volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Dynavax Technologies quarterly revenues are $72M, which are smaller than Moderna quarterly revenues of $956M. Dynavax Technologies's net income of $7.1M is higher than Moderna's net income of -$1.1B. Notably, Dynavax Technologies's price-to-earnings ratio is 60.11x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 5.58x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.